Objective. The aim of this study was to determine the pattern of use of pregabalin and the appropriateness of treatment, so that interventions could be designed to improve various clinical approaches to the use of pregabalin to include unlicensed indications.
Introduction
Currently, moderate to severe chronic pain affects approximately 18% of the population across Europe [1] . In addition, management of chronic pain is a major clinical challenge. It has long been recognized that the perception of pain, and the disability that often arises from it, is inextricably linked to an individual's emotional, cognitive, and social functioning. The available pain management strategies include a wide range of both pharmacological and nonpharmacological strategies [2] .
Pregabalin is an analogue of gamma-aminobutyric acid (GABA) that, due to its mechanism of action, has analgesic, anxiolytic, and antiepileptic effects. In the European Union (EU), it is indicated for peripheral and central neuropathic pain, epilepsy, and generalized anxiety disorder (GAD) in adults [3] . According to the Cochrane Review [4] , pregabalin has proven efficacy against neuropathic pain conditions and fibromyalgia. There is no evidence to support the use of pregabalin in acute pain scenarios.
Pregabalin (titrated up to at least 300 mg daily) is generally recommended in guidelines [2] for the treatment of patients with neuropathic pain if other first-and secondline pharmacological treatments have failed. A flexible dosing strategy (manufacturer's recommended dosages between 150 and 600 mg per day were considered effective, based on clinical response and tolerability) [3] may reduce discontinuations, facilitate a higher final dose, and give slightly greater pain relief.
Official data published in Spain [5] on an analysis of the Anatomical Therapeutic Chemical (ATC) classification groups with the highest sales volumes from 1992 to 2006 revealed a very sharp increase in the use of antiepileptic drugs. The consumption of all the associated therapeutic subgroups remained more or less constant over the 15 years of the study, except for the subgroup "N03AX -Other antiepileptic drugs," which was responsible for approximately 80% of the increase in the total use of antiepileptic drugs since 1992. Gabapentin accounted for most of the consumption in this subgroup, mainly due to the fact that it is also indicated for "peripheral neuropathic pain." However, the consumption of other antiepileptic drugs also rose during the study period, including that of pregabalin (a drug authorized and funded by the Spanish National Health System in 2004). It should be considered that the volume of sales of pregabalin increased significantly between 2005 and 2006, which coincides with the European authorization of a new indication for neuropathic pain [3] .
Subsequent data on the consumption of pregabalin between 2007 and 2008 in Spain and specifically in Catalonia, a Spanish regional health administration, showed a further increase in the sales volume of over 40% [6, 7] . This situation may be due to the fact that in 2007 the US Food and Drug Administration approved pregabalin as the first drug indicated for the management of fibromyalgia [8] . This indication is not currently licensed in the EU [3] ; however, the European League Against Rheumatism (EULAR) [9] highly recommends pregabalin for fibromyalgia treatment and contends that it should be a firstline therapy.
The latest data source on pregabalin sales in Spain (2011-2014) [6] shows that it continued to top sales in monetary terms (millions of e), with figures of e145.51 M, e161.44 M, e175.05 M, and e184.37 M, respectively. In 2015, the first generic versions of this drug appeared on the market, and consequently its price dropped. This had an impact on sales volume (monetary value), which fell sharply (e109.78 M), and pregabalin moved into sixth place in the ranking by active substance [6] . However, the use of pregabalin went up in terms of the number of units prescribed and dispensed, while the price drop masked this effect. A similar pattern is found in the Catalan Health Service (CatSalut) data on pregabalin sales in Catalonia for 2013 to 2015 (from the second highest monetary sales in 2013 and 2014 to seventh in 2015) [7] .
The aim of this study was to determine the pattern of use of pregabalin and the appropriateness of treatment, so that interventions could be designed to improve various clinical approaches to the use of pregabalin to include unlicensed indications. Currently, Lyrica (pregabalin) is patented in Spain for only one indication: neuropathic pain. That patent expires in July 2017. The generic versions that have been marketed are only licensed for the treatment of epilepsy and GAD.
Methods

Design and Setting of the Study
A descriptive, cross-sectional, multicenter study was carried out between April 2014 and January 2015. It covered the 53 primary care teams in the Department of Primary Care (DAP) Costa de Ponent of the Catalan Institute of Health (ICS), which provides health care for 1.25 million inhabitants.
The ICS [10] is the main public provider of health services in Catalonia, Spain. It is a pioneer in its three basic areas of activity: health care (its main area), research, and teaching. The ICS provides health services to 83% of all Catalan citizens (more than 5.5 million people). It is comprised of eight hospitals and 287 primary care teams, located throughout the whole of Catalonia. The primary care teams are made up of a varying number of professionals (general practitioners, pediatricians, nurses, auxiliary nursing staff, dental surgeons, social workers, and administrative staff) and are responsible for providing public coverage in primary health care to the population that lives within their catchment area. DAPs are management structures that are directly responsible for all of the health centers, services, and institutions within their corresponding area. The DAP Costa de Ponent directly manages primary health care services in the southern Barcelona metropolitan area (Catalonia, Spain).
Data Sources
A total of 10,155 patients who were covered by the DAP Costa de Ponent and had a current prescription for pregabalin (cutoff date: May 19, 2014) were selected. The patients' clinical information was obtained from computerized health records (e-CAP computer program). e-CAP contains patients' demographic data, medical history, diagnoses, medications, treatment plans, immunization dates, allergies, radiology images, laboratory and test results, therapeutic procedures, hospital release dates, and visits to emergency facilities. e-CAP also allows clinical data provided by the private health sector or the individual citizen to be added later, so it contains information from other health providers and organizations involved in patient care [11] .
Data Collection and Variables
Information on each patient was recorded separately using a specially designed form, so that the data could subsequently be used in the analysis. To design the form, 124 computerized health records of patients with a current pregabalin prescription were selected from the e-CAP computer program and analyzed. Computerized health records were extracted from anonymized data. Diagnoses that could be associated with pregabalin use were identified and grouped together. The codes of other drugs used in combination with pregabalin were compiled to analyze which were most common, and available data on kidney function was included. Diseases were coded according to the 10th version of the International Statistical Classification of Diseases and Related Health Problems (ICD-10), and drugs were coded according to the World Health Organization (WHO) ATC classification system (Supplementary Appendix 1).
The study variables were both demographic (gender, age) and clinical (licensed pregabalin indications, treatment duration, dosing schedule, diagnoses, kidney function, previous treatment with pregabalin, and drug treatment in combination with pregabalin). Kidney function was assessed by glomerular filtration rate (GFR). According to data published on chronic kidney disease by the National Kidney Foundation, a GFR below 15 mL/min is considered the most serious and indicates kidney failure [12] .
The indicators were related to the daily dose of pregabalin (by age, gender, treatment duration, kidney function, and appropriate treatment in terms of dose), diagnoses (appropriateness according to indication or kidney function), and treatment (appropriateness according to diagnosis and daily dose or according to diagnosis and treatment duration).
Ethical Review Board Approval
Ethical approval was not required as this was a retrospective secondary analysis of suitably anonymized data sets. It was not an experimental study, and patients were not recruited. The study was not funded.
Data Analysis
Initially, a descriptive analysis of the data was carried out, in which discrete variables were expressed in proportions or frequencies, and continuous variables as means and standard deviations. Then, frequencies were compared in a bivariate analysis using v square, and means were compared using Student's t test or analysis of variance, depending on the number of variables to be analyzed. Results were considered statistically significant when the P value was 0.05 or less. The statistical analysis was carried out using SPSS 17.0 software.
A descriptive, cross-sectional, multicenter study of pregabalin use was carried out in the same setting in 2009 with a representative sample of patients (N ¼ 256). The previous results were compared with those of the study reported here [13] .
Results
Description of the Population: Demographic Data
The population of Catalonia in 2014 was 7,508,106, 0.14% lower than in 2013. In the DAP under study, which has four primary care services, the total population covered by the public health system was 1,206,219 in 2014 [10] .
On the cutoff date, 10,155 patients were taking pregabalin prescribed by one of the teams in the DAP under study. Therefore, an average of 8.4 patients per 1,000 inhabitants had a pregabalin prescription. Of these 10,155 patients, 64.2% (N ¼ 6,522) were women. The average patient age was 62.3 years (SD ¼ 15.2 years), 60.8 years for men and 63.2 years for women; the difference was statistically significant (P < 0.005). Patients were classified into four age groups: younger than 25 years (0.8% of patients), 25 to 50 years (22.6%), 51 to 65 years (31.8%), and older than 65 years (44.8%). Patient age varied from 10 to 101 years, so current pregabalin treatments were detected in the nonadult population: 29 patients were under 18 years old, a dosing schedule that is outside the age limits specified in the summary of product characteristics (SmPC) of pregabalin.
Description of the Population: Clinical Data
Pattern of Pregabalin Use
The length of treatment with pregabalin was studied; the average was 413.4 days (SD ¼ 523.2 days). A total 66.6% of patients had been treated for less than a Clinical Use of Pregabalin year (N ¼ 6,762), 14.6% for between one and two years (N ¼ 1,485), 12.6% for between two and four years (N ¼ 1,279), 4.7% for between four and six years (N ¼ 473), and 1.5% for more than six years (N ¼ 156).
The records of 202 patients did not specify the dosing schedule (153 patients) or were invalid (49 patients). Therefore, the analysis of dosing schedule results only refers to 9,953 patients ( Figure 1) . A wide range of dosing schedules was recorded: 11 in total, of which four could be considered subtherapeutic, according to SmPC.
The average daily dose administered to patients treated with pregabalin was 151 mg (SD ¼ 113.3 mg; minimum dose: 13 mg, maximum dose: 2,700 mg). Dosing schedules by gender, age group, length of treatment, and according to kidney function are represented in Figure  2 , A-D. Differences in average daily dose were statistically significant according to gender and for all the age groups (P < 0.005).
Between the shortest treatment group (patients with a treatment duration of less than a year, in which the average daily dose was lower) and the other groups, the differences between average daily dose were statistically significant (P < 0.005). In addition, there were statistically significant differences (P < 0.005) in average daily dose between the group that had been receiving treatment for one to two years and the group that had been treated for more than six years.
Significant differences were also found between the average daily dose according to GFR (P < 0.005). Not all the patients in the study were included in this analysis as the GFR was not known for all of them. In patients with GFRs lower than 15 mL/min, which is indicative of moderate or severe kidney failure [12] , the dose was higher than the recommended maximum in 47% of patients. Finally, when the maximum recommended dose according to kidney function was compared with the daily dose prescribed to patients in the study, it was found that 45 patients (0.4% of the total) were not prescribed an appropriate dose according to their GFR. Of these 45 patients, 20 (44%) were administered a higher daily dose than the authorized 600 mg.
Pregabalin was found to be prescribed for nine diagnoses ( Figure 3 ). Each patient may have had more than one specific diagnosis, which is why the results add up to over 100%.
To determine whether the diagnoses matched the drug indications, we considered that patients received appropriate treatment according to the drug indications (neuropathic pain, GAD, and epilepsy) when they had one or more appropriate diagnoses, even if they also had inappropriate diagnoses. A total of 68.2% of patients had at least one of the diagnoses licensed in the SmPC. A total of 6.9% of patients did not have any recorded diagnosis. Regarding whether diagnoses were appropriate or not according to patient kidney function, of the 45 patients who did not have a pregabalin dosing schedule adapted to their GFRs, 29% did not have a diagnosis that was considered appropriate.
Appropriateness of Treatment According to Diagnosis, Dosing Schedule, and Length of Treatment
Very similar patterns were found for the average daily dose prescribed according to whether or not the diagnosis was appropriate (in 50% of cases, the diagnosis did not warrant the prescription considering also dosing schedule and length of treatment). There were, however, significant differences (P < 0.05) between diagnostic groups ( Table 1 ). The average treatment duration was analyzed for both appropriate and inappropriate diagnoses (Table 2 ). Significant differences (P < 0.05) were found between some diagnostic groups. Table 3 shows the distribution of diagnoses according to treatment duration. The number of patients with each diagnosis did not add up to the total number of patients in the study as some patients had more than one diagnosis; therefore, the total corresponds to the number of diagnoses rather than the number of patients. In addition, an analysis of the appropriateness of the prescriptions and treatment durations (Figure 4) showed no significant differences (P > 0.05).
Drug Treatment Prior to Pregabalin
We assessed whether other drugs had been administered prior to the use of pregabalin to treat the same health problem. A total of 10.9% of patients had taken amitriptyline before starting treatment with pregabalin; 13.0% had taken gabapentin, 4.2% continued to take gabapentin or amitriptyline, and 71.9% had not taken either amitriptyline or gabapentin before starting treatment with pregabalin. A total of 66% of current treatments had started during the last year.
Drug Treatment in Combination with Pregabalin
Along with pregabalin, patients with neuropathic pain, bone and joint pain, fibromyalgia, spondylopathy and dorsopathy, depression, and neuralgia were prescribed various drugs for pain management (Supplementary Appendix 1). The drugs were compatible, so each patient could take more than one at a time. The drugs that were prescribed most frequently were analgesics (42.0% of patients), anxiolytics (35.4% of patients), and opioid analgesics (30.0% of patients). A total of 1.1% of patients took pregabalin and gabapentin concurrently. 
Discussion
The present study provides new information on the prescription patterns of pregabalin in general practice in Catalonia, Spain. The prevalence and incidence of pregabalin use associated with specific indications, according to recorded diagnoses, were determined on the basis of clinical information available from the e-CAP database [11] . We linked several demographic and clinical characteristics to pregabalin use. To our knowledge, this is the first study that provides novel information regarding the prescription of pregabalin in patients with renal impairment. However, some limitations should be considered.
This study is based on prescription data, so we cannot ascertain whether the prescriptions were actually used or whether the drugs were taken by the patient.
Secondly, the clinical diagnoses made by general practitioners may not be accurate, so all pregabalin prescriptions were analyzed, whether or not they were linked to licensed indications. The study was carried out using data collected from a restricted area of northeastern Figure 3 Distribution of patients according to the nine diagnoses encountered.
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Spain; therefore, our findings may not be applicable to the entire Spanish population. However, the evidence in the literature and comparison with a previous study carried out in the same setting in 2009 [13] support the results on pregabalin use, at least in this area.
Other potential indications for pregabalin are under study, despite controversial results. The frequent offlabel use of pregabalin in clinical populations is found in both primary and specialized care (perioperative settings and analgesia/anesthesia protocols) [14, 15] . Others have studied the potential for pregabalin abuse and dependence [16] .
Characteristics of the Population with Pregabalin Prescriptions
The population distribution by gender and age was similar to that observed in the previous study carried out in 2009 in the same area [13] .
The prevalence of pregabalin prescription by gender did not differ among patients with conditions for which the drug is licensed in the EU [3] . However, pregabalin is also used for conditions such as fibromyalgia and bone and joint pain (off-label use), and in this case current prescriptions were more prevalent among women. In the EPISER study (in 2000) [17] , the prevalence of fibromyalgia in the Spanish population was estimated at 2.4%, with 4.2% for women and 0.2% for men. It is important to note that pregabalin was authorized in Spain in July 2004, so this could explain the differences between the EPISER study and our results. The fibromyalgia prevalence data from the EPISER study also contrast with a prevalence close to 10% in countries such as Israel, the United States, the United Kingdom, and Canada [18] . As the diagnostic criteria are only clinical and the etiopathogenesis has not yet been clarified, it is very difficult to study and determine a therapeutic approach to fibromyalgia and to make epidemiological comparisons between countries. As for the distribution of the study population by gender, the average age of patients (62.3 years) was an expected result, considering that the geriatric population suffers more from chronic pain. In a study of 18,626 patients carried out from 2005 to 2009 in Stockholm [19] , it was found that the average ages of men and women who used pregabalin were 62 and 64 years, respectively.
Pattern of Pregabalin Use
Two-thirds of patients had been undergoing treatment with pregabalin for less than a year. In the previous study carried out in 2009, 50% of the patients had been treated for less than a year [13] . This change could be due to the fact that treatments are now shorter or that more new treatments are being started. With reference to the high variability in the dosing schedules, our results agreed with the previous study [13] .
The licensed dose according to the SmPC is very similar for the three indications of pregabalin. Generally, pregabalin treatment can be started at a dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after an interval of three to seven days and, if needed, to a maximum dose of 600 mg per day after an additional seven-day interval [3] . Notably, 41.2% of patients had a dosing schedule lower than that indicated, which could lead to a lack of effectiveness of the treatment.
In patients older than age 25 years, the average daily dose decreased as the age range increased. This result was found to be statistically significant (P < 0.005) and was expected [13] . Older patients require lower doses due to a reduction in kidney function. Women were prescribed lower doses than men, although no difference by gender is specified in the SmPC [3] . The analysis of daily dose according to treatment duration showed that the patients with the lowest average daily dose were those whose treatment had lasted less than a year. This could be due to a lack of effectiveness, which becomes evident the longer the treatment lasts. In the study carried out in 2009 [13] , the average daily dose was also higher in patients who were treated for more than a year.
Characteristics of Diagnoses and Licensed Indications of Pregabalin
Only 68.2% of patients had at least one of the diagnoses warranting pregabalin prescription. The International Association for the Study of Pain (IASP) [20] defines neuropathic pain as pain caused by a lesion or disease of the somatosensory nervous system. Neuropathic pain is a clinical description (not a diagnosis) requiring a demonstrable lesion or a disease that satisfies established neurological diagnostic criteria. Neurologists generally consider pain to be neuropathic when there is a clear lesion of the nervous system [21] . However, the IASP definition is broader, and the fact that it includes the term "dysfunction" could mean that pathologies Only 0.7% of patients took pregabalin to treat epilepsy, which shows that, despite the fact that this drug belongs to the group of antiepileptics, it is mainly used for other indications.
In terms of the evaluation of appropriate treatment according to diagnosis and daily dose, our results differed from those of the study carried out in 2009 [13] in the same DAP, in which the daily dose of patients with an appropriate diagnosis was higher than that of patients with an inappropriate diagnosis. This could be due to an increase in the number of patients with bone and joint pain or dorsopathy without radiculopathy diagnoses, which are not authorized pregabalin indications [3] .
In the case of diagnoses that are not included in the SmPC [3] , such as bone and joint pain or fibromyalgia, the treatment durations were longer than those of licensed indications such as GAD or epilepsy. This result, also observed in the study undertaken in 2009 [13] , is surprising and could be due to the fact that treatments for bone and joint pain tend to be continued for longer.
Treatment Alternatives to Pregabalin
Regarding the review of previous drug treatment, it was found that approximately 72% of the patients did not have a prescription for either gabapentin or amitriptyline for the same health problem before they were prescribed pregabalin. In contrast to the results of our study presented here, Wettermark et al. [19] showed that 55% of patients had used antidepressants, 49% had used opioids, and 48% had used sedatives before they started treatment with pregabalin.
A retrospective study of administrative records in Sweden (2004 Sweden ( -2009 [22] to explore treatment patterns in patients with chronic pain diagnoses and the initiation of pharmacological treatment indicated for neuropathic pain showed different results from those presented here. Of the patients who were assumed to be treated for neuropathic pain, 16% had a neuropathy diagnosis, 18% had a mixed pain diagnosis, and the remaining 66% had another diagnosis related to chronic pain. The most common first prescription was amitriptyline (40%), followed by pregabalin (22%) and gabapentin (19%). More than half of the patients had discontinued treatment at three months, and 60% to 70% at six months; 7% of those who discontinued this treatment switched to or remained on another analgesic drug. A small proportion of patients (11%) had an added analgesic prescription in parallel to the pharmacological treatment indicated for neuropathic pain, and more than one-fifth (22%) of patients were also prescribed a psychiatric drug (selective serotonin reuptake inhibitor or benzodiazepines).
Gabapentin and amitriptyline have been on the market longer than pregabalin, and there is abundant evidence of their effectiveness and safety. Reports by Spanish pharmacotherapeutic committees recommend the use of gabapentin or amitriptyline prior to pregabalin [5, 10] , which is consistent with the National Institute for Health and Care Excellence (NICE) guidelines on the treatment of neuropathic pain (2012) [23] and the Cochrane review by Wiffen et al. [24] , which concluded that clinical trials support the use of gabapentin and pregabalin in some neuropathic pain conditions (painful diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain) and fibromyalgia. For other antiepileptic drugs, there was no evidence, insufficient evidence, or evidence of a lack of effect, although clinical practice experience indicates that some patients can achieve good results with antiepileptics other than gabapentin or pregabalin. In December 2014, the Canadian Agency for Drugs and Technologies in Health [25] concluded that the efficacy of gabapentin was similar to that of antidepressants and pregabalin in relieving pain in diabetic neuropathy, postherpetic neuralgia, and fibromyalgia.
In this study, coprescriptions with pregabalin of other analgesics were most frequently found in nonneuropathic pain conditions such as bone and joint pain and spondylopathy without radiculopathy, and coprescriptions of other anxiolytics were most frequently found in GAD. Patients with concurrent prescriptions for gabapentin and pregabalin were also found (1.1%; N ¼ 114); these two drugs have the same mechanism of action, and although no pharmacokinetic interactions between them have been reported, pregabalin may displace gabapentin from receptors [3] .
Strategies to Improve Results
Potential interventions include studying the safety and efficacy of pregabalin in patients younger than age 18 years, flagging inappropriate doses according to GFR for review and possible dose reduction, sending reminders to doctors about indications for pregabalin, and providing information on inappropriate diagnoses and alternatives to pregabalin.
Another opportunity for improvement would be to replace pregabalin with gabapentin in patients with neuropathic pain, based on costs and safety. Both gabapentin and pregabalin were initially developed as antiepileptic drugs. Both agents are also licensed for use in neuropathic pain, on the basis of scientific evidence. The mechanism of action is similar in both drugs. However, it is important to note that gabapentin has nonlinear pharmacokinetics, which means that the dose needs to be carefully adjusted. In this way, if pregabalin treatment needs to be withdrawn or replaced with an alternative drug, the dose should be gradually reduced over at least a week. This minimizes the risk of a greater frequency of crises for patients with convulsive disorders. [3] The procedure for replacing pregabalin with gabapentin consists of remembering that the standard dosing schedule for pregabalin is 150 mg per 12 hours (maximum daily dose of 600 mg), while that of gabapentin is 600 mg per eight hours (maximum daily dose of 3,600 mg).
The principal clinical practice guidelines recommend amitriptyline as the firstline treatment for neuropathic pain, except in trigeminal neuralgia, in which the use of carbamazepine is recommended, and when the complications associated with TCAs are prevalent, such as in older adults. If there is a lack of response, intolerance, or a partial but insufficient response to amitriptyline, the ICS Pharmacotherapeutic Commission recommends changing to or adding gabapentin, which leaves pregabalin as the third choice of drug [10] . According to the NICE [23] publication and in the absence of more detailed data, recommendations cannot be made about initiating or switching to gabapentin following pregabalin treatment or vice versa. The individual SmPCs [3] suggest that either agent can be discontinued over the course of a week, although whether this is relevant for patients with neuropathic pain remains unclear.
Conclusions
This study supports other literature demonstrating that pregabalin is used frequently off-label and for unlicensed indications in both primary care and hospital care (in the perioperative setting and analgesia/anesthesia protocols) settings. These findings indicate the need for better training to improve diagnostic and prescription procedures for achieving better treatment outcomes. Our study also provides novel information about the frequency with which patients with renal impairment are prescribed doses of pregabalin that exceed clinical recommendations.
